Clinical and biochemical factors associated with prognosis after myocardial infarction at a young age

Department of Cardiology, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden.

OBJECTIVES. This study examined the effect of metabolic disturbances, hemostatic function, coronary artery disease severity and left ventricular function on the long-term prognosis after myocardial infarction in men < 45 years old. BACKGROUND. Heavy smoking; dyslipoproteinemias involving very low density lipoprotein (VLDL), low density lipoprotein (LDL) and high density lipoprotein (HDL); a family history of premature coronary artery disease; hyperinsulinemic responses to oral and intravenous glucose challenges; and defective fibrinolytic function characterize the young postinfarction patient, but the influence of these features on the long-term prognosis is virtually unknown. METHODS. Measurements of hemostatic function and metabolic and angiographic indicators of risk were included in a prospective cohort study of variables predictive of reinfarction, cardiac death and major coronary events within 6 to 9 years in 108 unselected nondiabetic men with a first myocardial infarction before age 45 years. RESULTS. During follow-up, 20 patients had sudden cardiac death, and 53 had a major coronary event (reinfarction, sudden cardiac death, bypass surgery or intervention by catheterization). In multivariate analysis, VLDL and global coronary atherosclerosis score predicted reinfarction; plasma plasminogen activator inhibitor-1 (PAI-1) activity and global coronary stenosis score predicted cardiac death; and VLDL triglyceride levels, global coronary atherosclerosis score and age predicted any major coronary event. CONCLUSIONS. This prospective cohort study shows that hypertriglyceridemia, impaired fibrinolytic capacity secondary to plasma PAI-1 activity elevation and extensive coronary artery disease increase the risk of recurrences in men with a first myocardial infarction before age 45 and contribute to the relatively poor long-term prognosis in this patient group.

This article has been cited by other articles:

				M Egred, G Viswanathan, and G K Davis Myocardial infarction in young adults Postgrad. Med. J., December 1, 2005; 81(962): 741 - 745. [Abstract] [Full Text] [PDF]

				M. Okada, T. Saito, H. Yoshimura, Y. Noguchi, T. Ito, H. Sasaki, and H. Hama Surfactant-Based Homogeneous Assay for the Measurement of Triglyceride Concentrations in VLDL and Intermediate-Density Lipoprotein Clin. Chem., October 1, 2005; 51(10): 1804 - 1810. [Abstract] [Full Text] [PDF]

				M. Cesari and G. P. Rossi Plasminogen Activator Inhibitor Type 1 in Ischemic Cardiomyopathy Arterioscler. Thromb. Vasc. Biol., June 1, 1999; 19(6): 1378 - 1386. [Full Text] [PDF]

				B. A. Allison, L. Nilsson, F. Karpe, A. Hamsten, and P. Eriksson Effects of Native, Triglyceride-Enriched, and Oxidatively Modified LDL on Plasminogen Activator Inhibitor-1 Expression in Human Endothelial Cells Arterioscler. Thromb. Vasc. Biol., May 1, 1999; 19(5): 1354 - 1360. [Abstract] [Full Text] [PDF]

				P. Eriksson, L. Nilsson, F. Karpe, and A. Hamsten Very-Low-Density Lipoprotein Response Element in the Promoter Region of the Human Plasminogen Activator Inhibitor-1 Gene Implicated in the Impaired Fibrinolysis of Hypertriglyceridemia Arterioscler. Thromb. Vasc. Biol., January 1, 1998; 18(1): 20 - 26. [Abstract] [Full Text] [PDF]

				Y. Hong, N. L. Pedersen, N. Egberg, and U. de Faire Moderate Genetic Influences on Plasma Levels of Plasminogen Activator Inhibitor-1 and Evidence of Genetic and Environmental Influences Shared by Plasminogen Activator Inhibitor-1, Triglycerides, and Body Mass Index Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 2776 - 2782. [Abstract] [Full Text]

				D. J. Schneider, M. A. Ricci, D. J. Taatjes, P. Q. Baumann, J. C. Reese, B. J. Leavitt, P. M. Absher, and B. E. Sobel Changes in Arterial Expression of Fibrinolytic System Proteins in Atherogenesis Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 3294 - 3301. [Abstract] [Full Text]

				A. Basile-Borgia and J. H Abel Lipoproteins in heart disease Perfusion, January 1, 1996; 11(4): 338 - 345. [Abstract] [PDF]

				E. Haber Angiotensin-Converting Enzyme and Lipoprotein(a) as Risk Factors for Myocardial Infarction Circulation, March 15, 1995; 91(6): 1888 - 1890. [Full Text]